

Date: August 4, 2023

BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Outcome of the meeting of the Committee of Directors (Rights Issue) of Piramal Pharma Limited (“Company”) dated August 4, 2023, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI Listing Regulations”)

Dear Sir/Madam,

This is further to (i) our intimation on the outcome of the meeting of the board of directors of the Company dated February 8, 2023, where the issue of fully paid-up equity shares of the Company of face value of ₹10 each was approved by way of a rights issue for an amount not exceeding ₹1,050 crore (“**Rights Issue**”), in accordance with the Companies Act, 2013 and the rule made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended and other applicable laws; and (ii) our intimation dated July 27, 2023 in connection with the meeting of the Committee of Directors (Rights Issue) (“**Committee**”) approving, *inter alia*, the Rights Issue price, rights entitlement ratio, the record date and the Rights Issue period.

Please note, with respect to the letter of offer dated July 27, 2023 (“**Letter of Offer**”) filed with the Securities and Exchange Board of India, BSE Limited and National Stock Exchange of India Limited, the Committee at its meeting held today, August 4, 2023, has extended the Rights Issue period by one day. The Rights Issue will now close on August 17, 2023. Accordingly, all references to the Issue Closing Date in the Letter of Offer, abridged letter of offer, application forms and all other documents connected with the Rights Issue should be read as per the new closing date i.e., August 17, 2023.

This intimation is issued in terms of Regulation 30 of the SEBI Listing Regulations.

You are requested to kindly take note of the same.

For Piramal Pharma Limited

Tanya Sanish
Company Secretary

Piramal Pharma Limited

CIN: U24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T: +91 22 3802 3000 / 4000

piramal.com